288 related articles for article (PubMed ID: 30085142)
1. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Lin AL; Jonsson P; Tabar V; Yang TJ; Cuaron J; Beal K; Cohen M; Postow M; Rosenblum M; Shia J; DeAngelis LM; Taylor BS; Young RJ; Geer EB
J Clin Endocrinol Metab; 2018 Oct; 103(10):3925-3930. PubMed ID: 30085142
[TBL] [Abstract][Full Text] [Related]
2. Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease.
Joehlin-Price AS; Hardesty DA; Arnold CA; Kirschner LS; Prevedello DM; Lehman NL
Diagn Pathol; 2017 Apr; 12(1):34. PubMed ID: 28420444
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Sol B; de Filette JMK; Awada G; Raeymaeckers S; Aspeslagh S; Andreescu CE; Neyns B; Velkeniers B
Eur J Endocrinol; 2021 Jan; 184(1):K1-K5. PubMed ID: 33112279
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
5. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Tanaka S; Yamamoto M; Morita M; Takeno A; Kanazawa I; Yamaguchi T; Yamada S; Inoshita N; Oki Y; Kurosaki M; Sugimoto T
Endocr J; 2019 Aug; 66(8):701-708. PubMed ID: 31130573
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.
Greenman Y; Stern N
Pituitary; 2016 Dec; 19(6):605-611. PubMed ID: 27639583
[TBL] [Abstract][Full Text] [Related]
7. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
8. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.
Seltzer J; Ashton CE; Scotton TC; Pangal D; Carmichael JD; Zada G
Neurosurg Focus; 2015 Feb; 38(2):E17. PubMed ID: 25639319
[TBL] [Abstract][Full Text] [Related]
9. Transformation of a pituitary macroadenoma into to a corticotropin-secreting carcinoma over 16 years.
Brown RL; Wollman R; Weiss RE
Endocr Pract; 2007 Sep; 13(5):463-71. PubMed ID: 17872347
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
12. Immune-checkpoint inhibitors in pituitary malignancies.
Di Nunno V; Franceschi E; Tosoni A; Gatto L; Maggio I; Lodi R; Bartolini S; Brandes AA
Anticancer Drugs; 2022 Jan; 33(1):e28-e35. PubMed ID: 34348358
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
14. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Donovan LE; Arnal AV; Wang SH; Odia Y
CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
[TBL] [Abstract][Full Text] [Related]
15. ACTH-Cell Pituitary Adenoma With Signet Ring Cells: A Rare Case Report and Review of The Literature.
Trabzonlu L; Agirlar Trabzonlu T; Gurbuz Y; Ceylan S
Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):e13-e16. PubMed ID: 32044887
[TBL] [Abstract][Full Text] [Related]
16. Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease.
Suárez-Llanos JP; Fernández-Fernández E; Checa MR; Jara-Albarrán A
Neuro Endocrinol Lett; 2007 Oct; 28(5):549-53. PubMed ID: 17984930
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma.
Foltyn W
Endokrynol Pol; 2022; 73(2):375-376. PubMed ID: 35381097
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Duhamel C; Ilie MD; Salle H; Nassouri AS; Gaillard S; Deluche E; Assaker R; Mortier L; Cortet C; Raverot G
J Pers Med; 2020 Aug; 10(3):. PubMed ID: 32823651
[TBL] [Abstract][Full Text] [Related]
19. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
